The determination of some hormonal imbalance in the women with PCOS and verifying their effect on calcium homeostasis
DOI:
https://doi.org/10.32792/utq/utjsci/v12i2.1500Abstract
Polycystic ovarian syndrome is a common endocrinopathy in reproductive-aged women, associated with metabolic dysfunction influencing mineral metabolism and calcium regulatory pathway and affecting bone health. Thus, this study conducted to pinpoint specific hormonal abnormalities in PCOS women and to elevate their correlation with calcium homeostasis markers. A hundred specimen recruited from Iraqi women (50 PCOS patient and 50 serving as a control group (aged 18-40 years old). PCOS group was diagnosed according to standard Rotterdam criteria and were compared with controls without PCOS compatible in age and BMI. Blood samples were collected to quantify E2, LH, FSH, P.TH, Ca2+, and total testosterone by using hormone’s analyzer Addendum-Mini VIDAS apparatus (VIDAS) 12 mode l0, 1992. The PCOS group demonstrated higher LH, testosterone and calcium levels (4.96 ± 1.00) (0.64 ± 0.17) (10.37 ± 0.86) respectively, with decreased E2 and P.TH (55.12 ± 14.67) (25.08 ± 4.54) respectively when compared with control group, while FSH remained statistically unchanged. The data revealed a robust positive calcium-E2 correlation and an inverse E2-testesterone correlation implying a potential link between calcium homeostasis and ovarian steroidogenesis.
Received: 2025-10-18
Revised: 2025-11-13
Accepted: 2025-11-26
References
[1] C. C. Huang, Y. J. Tien, M. J. Chen, C. H. Chen, H. N. Ho, and Y. S. Yang, "Symptom patterns and phenotypic subgrouping of women with polycystic ovary syndrome: association between endocrine characteristics and metabolic aberrations," Hum. Reprod., vol. 30, pp. 937–946, 2015.
[2] Y. Han, Q. Cao, X. Qiao, and W. Huang, "Effect of vitamin D supplementation on hormones and menstrual cycle regularization in polycystic ovary syndrome women: A systemic review and meta-analysis," J. Obstet. Gynaecol. Res., vol. 49, no. 9, pp. 2232–2244, 2023.
[3] R. Azziz, “Polycystic ovary syndrome,” Obstetrics & Gynecology, 132(2), 321-336, 2018.
[4] C. M. Burt Solorzano, J. P. Beller, M. Y. Abshire, J. S. Collins, C. R. McCartney, and J. C. Marshall, "Neuroendocrine dysfunction in polycystic ovary syndrome," Steroids, vol. 77, pp. 32–37, 2012.
[5] K. Skrypnik, D. Pluta, M. Wojtowicz, T. B. Rhaiem, and J. Suliburska, "Association between serum levels of calcium, magnesium, iron and copper and insulin resistance in women with full blown and not-full blown phenotypes of polycystic ovary syndrome," Ginekologia Polska, vol. 95, no. 10, pp. 770–778, 2024.
[6] A. Ahmed, M. A. Saleem, F. Saeed, M. Afzaal, A. Imran, S. Akram, ... and E. Al Jbawi, "A comprehensive review on the impact of calcium and vitamin D insufficiency and allied metabolic disorders in females," Food Sci. Nutr., vol. 11, no. 9, pp. 5004–5027, 2023.
[7] M. Das, D. Djahanbakhch, B. Hacihanefioglu, E. Saridogan, M. Ikram, L. Ghali, M. Raveendran, and A. Storey, "Granulosa cell survival and proliferation are altered in polycystic ovary syndrome," J. Clin. Endocrinol. Metab., vol. 93, no. 3, pp. 881–887, 2008.
[8] P. Anagnostis, S. Karras, and D. G. Goulis, "Vitamin D in human reproduction: A narrative review," Int. J. Clin. Pract., vol. 67, no. 3, pp. 225–235, 2013.
[9] M. Brzozowska and A. Karowicz-Bilińska, "The role of vitamin D deficiency in the etiology of polycystic ovary syndrome disorders," Ginekologia Polska, vol. 84, no. 6, pp. 456–460, 2013.
[10] J. Ott, L. Wattar, C. Kurz, et al., "Parameters for calcium metabolism in women with polycystic ovary syndrome who undergo clomiphene citrate stimulation: A prospective cohort study," Eur. J. Endocrinol., vol. 166, pp. 897–902, 2012.
[11] Z. Shojaeian, R. Sadeghi, and R. L. Roudsari, “Calcium and vitamin D supplementation effects on metabolic factors, menstrual cycles and follicular responses in women with polycystic ovary syndrome: A systematic review and meta-analysis,” Caspian J. Intern. Med., vol. 10, no. 4, p. 359, 2019.
[12] D. E. Clapham, “Calcium signaling,” Cell, vol. 131, pp. 1047–1058, 2007.
[13] C. Chen, C. Chen, et al., “Calcium signaling in oocyte quality and functionality and its application,” Front. Endocrinol., vol. 15, article 1411000, 2024.
[14] J.-C. Huang, et al., “10H2DA improves PCOS through autophagy-mediated mitochondrial fission dependent on the maintenance of calcium homeostasis between endoplasmic reticulum and mitochondria,” Food Sci. Hum. Wellness, 2024.
[15] S. Zheng, L. Shanliang, et al., “Calcium homeostasis and cancer: insights from endoplasmic reticulum-centered organelle communications,” Trends Cell Biol., vol. 33, no. 4, pp. 312–323, 2023.
[16] T.G. Meng, et al., “NLRP14 safeguards calcium homeostasis via regulating the K27 ubiquitination of Nclx in oocyte-to-embryo transition,” Adv. Sci., vol. 10, no. 27, p. 2301940, 2023.
[17] A. Sharma and C. K. Welt, “Practical approach to hyperandrogenism in women,” Med. Clin., vol. 105, no. 6, pp. 1099–1116, 2021.
[18] I. Albanese and N. Garfield, “A case report of hyperestrogenism in Prader-Willi syndrome,” AACE Clin. Case Rep., vol. 8, no. 1, pp. 6–7, 2022.
[19] C. N. Jayasena, et al., “Society for endocrinology guideline for understanding, diagnosing and treating female hypogonadism,” Clin. Endocrinol. (Oxf)., vol. 101, no. 5, pp. 409–442, 2024.
[20] K. Dawale, A. Agrawal, and A. K. Agrawal, “Parathyroid hormone secretion and related syndromes,” Cureus, vol. 14, no. 10, 2022.
[21] A. Guzman, et al., "Menstrual cycle related fluctuations in circulating markers of bone metabolism at rest and in response to running in eumenorrheic females," Calcif. Tissue Int., vol. 111, no. 2, pp. 124–136, 2022.
[22] P. Srisuwarn, P. Praopilad, and S. Disthabanchong, "Role of parathyroid hormone and parathyroid hormone-related protein in protein-energy malnutrition," Front. Biosci. (Landmark Ed.), vol. 28, no. 8, p. 167, 2023.
[23] I. Naqvi, et al., "polycystic ovarian syndrome: A Review of Multi-omics Analyses," Reprod. Sci., vol. 32, no. 3, pp. 618–646, 2025.
[24] M. J. Jia, et al., "Genetically predicted serum metabolites mediate the association between inflammatory proteins and polycystic ovary syndrome: a Mendelian randomization study," Front. Med., vol. 11, article 1433612, 2024.
[25] B. Gao, et al., "Causal association between low vitamin D and polycystic ovary syndrome: a bidirectional Mendelian randomization study," J. Ovarian Res., vol. 17, no. 1, p. 95, 2024.
[26] A. Mohan, et al., "Vitamin D and polycystic ovary syndrome (PCOS): a review," Ann. Med. Surg., vol. 85, pp. 3506–3511, 2023.
[27] S. V. Joice, et al., "Effect of Vitamin D and Calcium Supplementation on Menstrual Abnormalities, Follicular Response and Metabolic Status in Polycystic Ovary Syndrome: A Systematic Review," J. Clin. Diagn. Res., vol. 19, no. 4, 2025.
[28] D Haarburger, et al., "Relationship between vitamin D, calcium and parathyroid hormone in Cape Town", J.clin.path.,vol.62, no.6,2009.
[29] S. K. Agarwal, H. L. Judd, and D. A. Magoffin, "A mechanism for the suppression of estrogen production in polycystic ovary syndrome," J. Clin. Endocrinol. Metab., vol. 81, no. 10, pp. 3686–3691, 1996.
[30] R. Pasquali, V. Vicennati, D. Bertazzo, et al., "Determinants of sex hormone–binding globulin blood concentrations in premenopausal and postmenopausal women with different estrogen status," Metab., vol. 46, no. 1, pp. 5–9, 1997.
[31] D. Panidis, D. Dimitriadis, et al., "Serum parathyroid hormone concentrations are increased in women with polycystic ovary syndrome," Clin. Chem., vol. 51, no. 9, pp. 1691–1697, 2005.
[32] S. Gaberšček, S. Bole, et al., "Mechanisms in endocrinology: thyroid and polycystic ovary syndrome," Eur. J. Endocrinol., vol. 172, pp. R9–R21, 2015.
[33] N. Malini and K. Roy George, "Evaluation of different ranges of LH:FSH ratios in polycystic ovarian syndrome (PCOS) – Clinical based case control study," Gen. Comp. Endocrinol., vol. 260, pp. 51–57, 2018.
[34] Z. Saadia, "Follicle stimulating hormone (LH: FSH) ratio in polycystic ovary syndrome (PCOS) – obese vs. non-obese women," Med. Arch., vol. 74, no. 4, p. 289, 2020.
[35] J. S. Laven, "Follicle stimulating hormone receptor (FSHR) polymorphisms and polycystic ovary syndrome (PCOS)," Front. Endocrinol., vol. 10, article 1023, 2019.
[36] A. Bushell and B. J. Crespi, "The evolutionary basis of elevated testosterone in women with polycystic ovary syndrome: an overview of systematic reviews of the evidence," Front. Reprod. Health, vol. 6, p. 1475132, 2024.
[37] P. Simons, I. H. G., et al., "The relationships of sex hormone–binding globulin, total testosterone, androstenedione and free testosterone with metabolic and reproductive features of polycystic ovary syndrome," Endocrinology, Diabetes & Metabolism, vol. 4, no. 3, e00267, 2021.
[38] S. Sun, L. Shuliu, et al., "Unveiling the shared genetic architecture between testosterone and polycystic ovary syndrome," Scientific Reports, vol. 14, no. 1, article 23931, 2024.
Downloads
Published
License
Copyright (c) 2025 University of Thi-Qar Journal of Science
This work is licensed under a Creative Commons Attribution 4.0 International License.
